Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 5.63%
As of Wednesday, August 05, Sagimet Biosciences Inc.’s SGMT share price has surged by 5.63%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Commentary & Analysis
Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 6.29%
As of Tuesday, August 04, Sagimet Biosciences Inc.’s SGMT share price has surged by 6.29%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 8.02%
As of Monday, August 03, Sagimet Biosciences Inc.’s SGMT share price has dipped by 8.02%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 5.10%
As of Friday, July 17, Sagimet Biosciences Inc.’s SGMT share price has surged by 5.10%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 6.85%
As of Tuesday, July 14, Sagimet Biosciences Inc.’s SGMT share price has surged by 6.85%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | SGMT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $675.0 | $279.4 | 40% |
|
| Shares Out (Mil) | 53.1 | 54.3 | 49% |
|
| Institutional Ownership | 98.6% | 92.9% | 80% |
|
| Float (Mil) | 55.8 | 42.3 | 49% |
|
| Beta | 3.40 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 1,016 | 468 | 72% |
|
| Price Change (52-week) |
54.5% | 57.1% | 83% |
|
| Growth | SGMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (34.9%) | (10.1%) | 11% |
|
| EPS (5yr) | 57.8% | 15.4% | 95 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 10 | |
| Current EPS | ($0.264) | ($1.163) | ($1.372) | |
| Month Ago EPS | ($0.260) | ($1.222) | ($1.311) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.260) | ($1.222) | ($1.311) | |
| Year/Year Chg | 0.4% | (26.3%) | (2.8%) | |
| Financials | SGMT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($47) | ($43) | 16% |
|
| EPS (TTM) | ($1.249) | ($1.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $336 | $195 | 30% |
|
| Valuation | SGMT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.62 | 2.74 | 60% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SGMT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (23.5%) | (47.8%) | 19% |
|
| ROE | (24.4%) | (55.0%) | 22% |
|
| Liabilities to Assets | 2.8% | 29.8% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Sagimet Biosciences Inc. did not pass any screens on 9/9/2026.
